chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Fever of 103.3, strong chills, headache, weakness. Fever reduced over 7 hours with ibuprofen & acetaminophen. Second day (11/3/13) I had nausea and vomiting, weakness, headache. I have spent two days in bed with this reaction to the vaccination.
I quit taking the Valacyclovir when I had the 2nd Shingrix vaccination in January.  Pharmacy or doctor wouldn't tell me whether I needed to keep taking it or not.  I broke out again Friday, April 30.  I ordered a refill of the Valtrex online from pharmacy and picked it up on Saturday and have been taking it.  There is a small patch of bumps on my left buttox - same as always - before I started taking Valacylovir years ago.  Never is severe, just itching and nerve pain down my left leg.  I was trying to save money when I took the Shingrix but I guess I'm doomed.
Sore arm.  Severe chills.  low grade fever.  Most noticeable, was a severe dry cough that started the day after the vaccine and lasted 3 weeks.  After the second vaccine the cough returned, but lasted only two days.
Woke up on May 31st with shortness of breathe.  Went into Urgent care and was sent to Hospital with cardiac failure.  While in hospital they found pneumonia which was treated.  Was in hospital for 6 days and released with a life vest which i am still wearing.  Ejections Fraction while in hospital was 10-15 today it is 20-25.
muscle aches, joint discomfort, chills/hot flashes and large increase of existing tinnitus.  Started approximately eight hours after shot and began decreasing approximately18 hours after shot.  basically back to normal after 24 hours.
Vaccines administered at primary care office on 4/26/06. The next day, he spiked a fever to 105.3 and had a generalized seizure which lasted approximately 30-45 minutes and was stopped by administration of Valium in the Emergency room.  He returned to baseline by the next morning (approx 12 hours later).  He is currently being monitored in the hospital without any further sequelae.  Of note, he also has symptoms of a viral URI and a right otitis media (TM is bulging and non-mobile on exam).
arm discomfort; Vaccination site eryhtema; Vaccination site pain; This spontaneous case was reported by a consumer and describes the occurrence of LIMB DISCOMFORT (arm discomfort), VACCINATION SITE ERYTHEMA (Vaccination site eryhtema) and VACCINATION SITE PAIN (Vaccination site pain) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 08-Feb-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced LIMB DISCOMFORT (arm discomfort), VACCINATION SITE ERYTHEMA (Vaccination site eryhtema) and VACCINATION SITE PAIN (Vaccination site pain). At the time of the report, LIMB DISCOMFORT (arm discomfort), VACCINATION SITE ERYTHEMA (Vaccination site eryhtema) and VACCINATION SITE PAIN (Vaccination site pain) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Information has been received from a physician concerning a 32 year old male, with hypertension, obesity, and possible diabetes, who on 02-OCT-2006, at 2:16 pm, was vaccinated with a 0.5 ml subcutaneous dose in the left of Varivax (Lot# 652806/0265F). Concomitant therapy included LOTENSIN. On 16-OCT-2006 the patient developed a pustule and a rash on his face and chest. It was noted that the reporter did not consider the event to be a breakthrough of varicella but a rash. Unspecified medical attention was sought. No product quality complaint was involved. No other information was provided. Follow-up information from a physician indicated that on 16-OCT-2006 the patient developed a fever and a varicella-like eruption on the face and chest. The reporter considered the patient's fever and varicella-like eruption to be disabling. Additional information has been requested.
Headache; weak; sleeping; tired/Fatigue; This is a spontaneous report from a contactable consumer (patient). A 60-year-old male patient received the second dose bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date at single dose for covid-19 immunization. There were no medical history or concomitant medications. The patient experienced headache, weak, sleeping, and tired/fatigue on an unspecified date. Event details: first it was headache and that had gone away and he was like weak, sleeping, tired and all. He was all weak and was fatigued at time of reporting, but he was all better. The patient did not receive treatment for the events. The outcome of events headache and sleeping was resolved, outcome of other events was resolving.   Information about batch/lot number has been requested.
Patient became pale, did not black out. Put patient on floor elevated leg/feet. BP checked initial 92/62, after 5 min 102/68, after 10 min 104/72
COVID-19; COVID-19; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient.  A 69-year-old male patient received BNT162b2 (BNT162B2), on 14Feb2021 at 11:00 as dose 1, single (Lot number: EN6200), in left arm, on 28Feb2021 at 11:00 as dose 2, single (Lot number: EN6203), in left arm and on 27Sep2021 as dose 3 (booster), single (Lot number: FF2588) at the age of 68 years, in left arm for covid-19 immunisation; coviD-19 vaccine mrna (mrna 1273) (MODERNA COVID-19 VACCINE), on 29Apr2022 as dose 4 (booster), single (Lot number: 004M21A), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Hypertension" (unspecified if ongoing). No known allergies. Concomitant medication(s) included: LOSARTIN. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 23Jul2022, outcome "recovering" and all described as "COVID-19". Adverse event resulted in none of the above. The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: symptoms & positive rapid test reoccurred about day 6. Therapeutic measures were taken as a result of drug ineffective, covid-19.  No follow-up attempts are possible. No further information is expected.
Patient was administered a covid monovalent vaccine instead of the bivalent booster. Patient has had no symptoms of any kind in regard to this.
Pfizer-BioNTech covid-19 Vaccine (2nd shot) 4/26/2021  Barely felt the injection/dose being administered and arm did not feel sore until 3 hours later. Did feel swelling of the throat on the left side with 30 minutes of shot but it was slight and only lasted a few minutes.  4/29-30/2021 Did have swelling of lymph nodes with the 2nd dose 4/30/2021 Did have a quick pain across the chest for a second or two in the morning while walking and a little tingling/numbness in the left arm for a few seconds As of 5/24/2021 still have a little soreness in left arm from the 1st dose. (occasionally), occasionally have a little burning/numbness in I arm and little finger/palm.
The next morning I woke up to both of my lips very swollen and painful; Later that day, my cheeks also started swelling and painful; Later that day, my cheeks also started swelling and painful; Approx 20 hours after receiving my 2nd dose, I felt a swelling in my lip in one spot, upper lip right side, just off center of my mouth. The next morning I woke up to both of my lips very swollen; This is a spontaneous report from a contactable consumer (Patient). A 41-years-old non pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number: EW0186 ), dose 2 intramuscularly, administered in Deltoid Right (Right arm) on 18May2021 at 15:15 (Age at vaccination: 41 years) as single dose for covid-19 immunisation. Vaccine Facility Type was Doctor's office/Urgent care. Patient medical history was none. Patient had none known allergies. The patient's concomitant medications were not reported. Patient received dose 1 on 27April2021 at 15:15, intramuscularly in right arm with lot number Ew0175. The patient did not receive any other vaccines within 4 weeks prior to COVID vaccine. Patient did not received any other medications within 2 weeks of the vaccination. Prior to vaccination the patient was diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient stated approx 20 hours after receiving her 2nd dose, she felt a swelling in her lip in one spot, upper lip right side, just off center of her mouth on 19May2021 at 11:00, the next morning on 20May2021, she woke up to both of her lips were very swollen and painful. Looked like she had major fillers done. she could hardly drink. later that day, her cheeks also started swelling and painful. Cheeks Felt similar to a sinus infection but in her whole cheeks on the bone area, almost ears to nose vs just sinus area. AE resulted in Doctor or other healthcare professional office/clinic visit. The patient received steroids for 5 days. The patient underwent lab tests and procedures which included sars-cov-2 test: positive on an unknown date. Device Date was reported as 20May2021. Physician consider the Pfizer product had a casual effect to the adverse event. The outcome of the events was unknown.
Lingering cough; Tested positive for COVID-19; This spontaneous case was reported by a consumer and describes the occurrence of COUGH (Lingering cough) and COVID-19 (Tested positive for COVID-19) in a 60-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 040A21A) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure high.    On 24-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 30-Mar-2021, the patient experienced COVID-19 (Tested positive for COVID-19). On 19-Apr-2021, the patient experienced COUGH (Lingering cough). At the time of the report, COUGH (Lingering cough) and COVID-19 (Tested positive for COVID-19) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 30-Mar-2021, SARS-CoV-2 test: positive (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       The patient has not taken any concomitant medication. No treatment information was reported.
Bilateral tinnitus.  Left ear tinnitus is worsethan right side.; This is a spontaneous report from a contactable healthcare professional. A 46-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration on 28Mar2021 (at the age of 46-years-old), as a single dose for COVID-19 immunisation. Medical history included mixed hyperlipidemia. The patient did not have any allergies to medications, food, or other products. The patient did not receive any other medications within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 28Mar2021 at 19:00, the patient experienced bilateral tinnitus since he got Pfizer COVID vaccine. The patient denied hearing loss and dizziness. Left ear tinnitus was worse than right side. The patient denied sleep issues. No intervention was needed, would continue to monitor. The patient advised it was his decision whether or not he should get the second COVID vaccine. The patient denied any history of tinnitus. The event resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event bilateral tinnitus, left ear tinnitus is worse than right side was not resolved at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
pt awoke from nap & back f head (scalp) swollen & hard;following day swelling resolved but episodes arching, standing, clenching jaw;
Case number PHEH2014US023336, is an initial spontaneous report from a pharmacist received on 19 Nov 2014. This report refers to a 64-year-old male patient. Medical history and concomitant medications were not reported. He was vaccinated with FLUVIRIN, (batch number: 1414101) intramuscularly twice in this Flu season on 07 Oct 2014 and on 18 Nov 2014. No adverse event was reported following this medication error (inappropriate schedule of vaccine administered).
Headache/migraine started 2 weeks after vaccination; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: MIGRAINE (non-serious), outcome "unknown", described as "Headache/migraine started 2 weeks after vaccination". The event "headache/migraine started 2 weeks after vaccination" was evaluated at the emergency room visit. Therapeutic measures were taken as a result of migraine.  Additional information: The event took place after use of product and ER visit was required for fluids.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Flu like symptons (no Nausea), pain, redness, below the injection site on arm, pain in joint of great toe, incipient migraine. Probably started night of Jan 4, bed rest/sleeping all of Jan 5, mostly resolved except for arm pain/redness (area approx 4" by 3") upon waking Jan 6.
pregnant patient was administered Arexvy on 10/18/2023; pregnant patient was administered Arexvy on 10/18/2023; This non-serious prospective pregnancy case was reported by a pharmacist via call center representative and described the occurrence of vaccine exposure during pregnancy in a 30-year-old female patient who received RSVPreF3 adjuvanted (Arexvy) (batch number 3AK2K, expiry date 09-DEC-2024) for prophylaxis.   On 18-OCT-2023, the patient received Arexvy. On 18-OCT-2023, an unknown time after receiving Arexvy, the patient experienced inappropriate age at vaccine administration (Verbatim: pregnant patient was administered Arexvy on 10/18/2023). On an unknown date, the patient experienced vaccine exposure during pregnancy (Verbatim: pregnant patient was administered Arexvy on 10/18/2023). The outcome of the vaccine exposure during pregnancy and inappropriate age at vaccine administration were unknown.   Pregnancy exposure: Pregnancy Exposure (Arexvy): Trimester unknown Pregnancy Outcome: Pregnancy was ongoing   Additional Information: GSK receipt date: 23-Oct-2023 The Vaccine Administration Facility was the same as Primary Reporter. The reporter was unsure of patient's gestational week.  The reporter consented to safety team for follow up. A pregnant patient received a dose of Arexvy at an inappropriate age, which led to vaccine exposure during pregnancy and inappropriate age at vaccine administration.
Pt was given varicella vaccine instead of ZOSTAVAX on 6/13/16.
Hives all over my body.  They have gotten less intense over time but I am still experiencing them over 4 months later.
My right arm goes numb several times a day, with pain at the injection site, the pain goes down my arm to my hands with this numb feeling. unexplained feeling that never happened before.
Achy arm in the night and then very weak and unable to use for full range of motion. Sharp pain in arm and unable to reach back or raise arm over head. Hurt during walking over 30 minutes. Went to chiropractor in November 14th and November 17 -ultrasound to reduce swelling in area of injury. In December went to MD and had Xray -showed no fractures, wanted MRI but declined by MD.
I have mild reactions to eating wheat or system shocks apparently linked to lupus. Had much more extreme inflammation reaction generally, to eating wheat products and dental anesthetic after 2nd vaccine. Still not fully recovered but improving.  Symptoms:  overall swelling of tissues, swelling of neck and face post anesthetic, very painful joints and muscles, increased skin sensitivity of feet, pins and needles. Chronic sleep issues due to pain. GI upset, including 4 weeks of green-colored feces and clear urine (even if took vit C/B). This cleared up after 2-3 weeks without any wheat products. Never experienced this before, apparently green color potentially linked to wheat intolerance and improper digestion of bile. Urine potentially linked to diabetes issues.
Patient with 3 Pfizer COVID vaccinations who admitted to hospital with COVID detected test.  Provider D/C note:  "94 YO year old male with past medical history of  HTN presenting to Hospital with complaint of generalized weakness. Patient is a poor historian.  He likes to joke around without giving any straight forward answer. He is complaining generalized weakness, more so on his legs. He was admitted for COVID infection.  During his hospital stay, his breathing status worsen and we offered remdesivir and steroid per COVID protocol, we discussed risk and benefit with daughter, she declined the plan. Family decided to switch him to comfort care and they signed with hospice. "
I got sicker with my 3rd dose of Modernae; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (I got sicker with my 3rd dose of Modernae) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ILLNESS (I got sicker with my 3rd dose of Modernae). At the time of the report, ILLNESS (I got sicker with my 3rd dose of Modernae) outcome was unknown.            No concomitant information was reported. No treatment information was reported. The year of birth of patient was 1949.   This case was linked to MOD-2022-546565 (Patient Link).
Initial unsolicited report received from a consumer on 15 April 2015. A female patient (age at onset unknown), whose medical history and concomitant medications were not reported, had received a INFLUENZA VACCINE (batch number, route of administration, site of administration was not reported) on an unspecified date. On an unspecified date after vaccination, the patient experienced flu. Laboratory investigations and corrective treatments were not reported. At the time of this report outcome of event was unknown. Documents held by sender: none.
pt recv vax 6PM on 28AUG96 parents noted enlarging red, warm area on thigh next day;brought pt to clinic;Md examined area & put pt on med;resolved in 3 days;
No additional adverse effect reported.; M-M-R II, VAQTA and GARDASIL 9 that underwent a temperature excursion (case 01907249) were administered.; This spontaneous report was received from a medical assistant referring to a patient of unknown age and gender. The patient's concurrent condition, pertinent medical history, concomitant medication, drug reactions or allergies were not reported.  On 10-FEB-2021, the patient was vaccinated with hepatitis a vaccine, inactivated (VAQTA) (lot #: T013204, expiration date: 03-DEC-2021 or lot #: T013546, expiration date: 28-OCT-2021 (two lot# of vaccines have been reported, no information of which one was administrated to the patient); dose, strength and route were not reported) for prophylaxis.          The vaccines underwent temperature excursions and were stored at 9 degree Celsius (C) to 25 C (8.7 C) for 30 minutes, 2 C to 8 C (8.2 C) for 30 minutes and 9 C to 25 C (9.43 C) for 45 minutes. There was no previous temperature excursion. The digital data logger was involved. No additional adverse effect reported.   This is one of 20 reports received from the same reporter. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: T013546; expirationdate: 28-OCT-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability; Sender's Comments:  US-009507513-2104USA002971: US-009507513-2104USA002970: US-009507513-2104USA002944: US-009507513-2104USA002963: US-009507513-2104USA002973: US-009507513-2104USA002974: US-009507513-2104USA002975: US-009507513-2104USA002976: US-009507513-2104USA002978: US-009507513-2104USA002980: US-009507513-2104USA002981: US-009507513-2104USA002982: US-009507513-2104USA002983: US-009507513-2104USA002984: US-009507513-2104USA002985: US-009507513-2104USA002986: US-009507513-2104USA002987: US-009507513-2104USA002988: US-009507513-2104USA002989:
Information has been received from a health professional concerning a 50 year old female who in approximately 1996 or 1998 was vaccinated with a dose of varicella virus vaccine live (Oka/Merck). In approximately 1996 or 1998 the patient experienced a chickenpox rash. The caller was not certain of the date of administration but stated that the patient received the vaccination in either 1996 or 1998. The patient experienced a mild case of chickenpox during that time period in which she received the vaccine. The patient was not being seen at the practice at the time of experiencing the chickenpox. There was no further information. The outcome was reported as recovered. There was no product quality complaint. Additional information has been requested.
The Patient is immunocompromised and receive the second booster  dose but instead of 0.25 ml the patient received 0.5 ml
I have redness, swelling, and pain in that area; I have redness in that area; I have swelling in that area; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site pain in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On 15-JUN-2023, the patient received Shingles vaccine. On 16-JUN-2023, 1 days after receiving Shingles vaccine, the patient experienced injection site pain (Verbatim: I have redness, swelling, and pain in that area), injection site erythema (Verbatim: I have redness in that area) and injection site swelling (Verbatim: I have swelling in that area). The outcome of the injection site pain, injection site erythema and injection site swelling were not resolved.   It was unknown if the reporter considered the injection site pain, injection site erythema and injection site swelling to be related to Shingles vaccine.     It was unknown if the company considered the injection site pain, injection site erythema and injection site swelling to be related to Shingles vaccine.   Additional Information: GSK Receipt date: 16-JUN-2023 A reporter reported about a patient who received Shingles vaccine yesterday and today on the day of reporting the patient experienced redness, swelling and pain in that area.  Patient wanted to know how long should she/he expect that to last this adverse event.
severe abd cramps, diarrhea, chills, h/a, low grade fever, fatigue;
The patient was given 0.5 ml of the booster moderna instead of the 0.25 ml. The patients first vaccine was johnson and johnson. Th patient has had no problems from the vaccine booster.